Inhibition of epidermal growth factor receptor over-expressing cancer cells by the aphorphine-type isoquinoline alkaloid, dicentrine

Biochemical Pharmacology

Volumn 79, Issue 8, 2010, Pages 1092-1099

  Konkimalla, V Badireenath ^a   Efferth, Thomas ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Microarrays; Natural product; Oncogenes; Pharmacogenomics; Pharmacognosy; Pharmacology; Signal transduction; Systems biology

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; AROMATIC HYDROCARBON RECEPTOR; BRCA1 PROTEIN; DICENTRINE; DNA; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; ISOQUINOLINE ALKALOID; MESSENGER RNA; PORPHOBILINOGEN DEAMINASE; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; EXPRESSION VECTOR; GENE DELETION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC SELECTION; GENETIC TRANSDUCTION; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MICROARRAY ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APORPHINES; BRCA1 PROTEIN; CELL CYCLE; CELL LINE, TUMOR; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77249160125     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.11.025     Document Type: Article

References (52)

1. Volm M., Kästel M., Mattern J., Efferth T. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 1993, 71:3981-3987.
2. Konkimalla V.B., Suhas V.L., Chandra N.R., Gebhart E., Efferth T. Diagnosis and therapy of oral squamous cell carcinoma. Expert Rev Anticancer Ther 2007, 7:317-329.
3. Hirsch F.R., Varella-Garcia M., Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small cell lung cancer. Oncogene 2009, 28(Suppl. 1):S32-S37.
4. Lemaire F., Millon R., Young J., Cromer A., Wasylyk C., Schultz I., et al. Differential expression profiling of head and neck squamous cell carcinoma (HNSCC). Br J Cancer 2003, 89:1940-1949.
5. Oliveira S., van Bergen en Henegouwen P.M., Storm G., Schiffelers R.M. Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. Expert Opin Biol Ther 2006, 6:605-617.
6. Astsaturov I., Cohen R.B., Harari P. Targeting epidermal growth factor receptor signalling in the treatment of head and neck cancer. Expert Rev Anticancer Ther 2006, 6:1179-1193.
7. Perea S., Hidalgo M. Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors. Clin Lung Cancer 2004, 6(Suppl. 1):S30-S34.
8. Lalezari I., Shafiee A., Mahjour M. Major alkaloids of Glaucium flavum Grantz, population Ghom. J Pharm Sci 1976, 65:923-924.
9. Shafiee A., Lalezari I., Rahimi O. Alkaloids of papaver genus IX. Alkaloids of Glaucium vitellinum Boiss and Buhse, population Seerjan and Glaucium pulchrum Stapf, population Elika. Lloydia 1977, 40:352-355.
10. Shafiee A., Lalezari I., Lajevardi S., Khalafi F. Alkaloids of Glaucium flavum Grantz, populations Isfahan and Kazerun. J Pharm Sci 1977, 66:873-874.
11. Vecchietti V., Casagrande C., Ferrari G. Alkaloids of Ocotea brachybotra. Farmaco [Sci] 1977, 32:767-769.
12. Vecchietti V., Casagrande C., Ferrari G., Severini Ricca G. New aporphine alkaloids of Ocotea minarum. Farmaco [Sci] 1979, 34:829-840.
13. Chen C.C., Huang Y.L., Ou J.C., Su M.J., Yu S.M., Teng C.M. Bioactive principles from the roots of Lindera megaphylla. Planta Med 1991, 57:406-408.
14. Stévigny C., Block S., De Pauw-Gillet M.C., de Hoffmann E., Llabrès G., Adjakidjé V., et al. Cytotoxic aporphine alkaloids from Cassytha filiformis. Planta Med 2002, 68:1042-1044.
15. Hoet S., Stévigny C., Block S., Opperdoes F., Colson P., Baldeyrou B., et al. Alkaloids from Cassytha filiformis and related aporphines: antitrypanosomal activity, cytotoxicity, and interaction with DNA and topoisomerases. Planta Med 2004, 70:407-413.
16. Tzeng C.C., Wu Y.C., Su T.L., Watanabe K.A., Lu S.T., Chou T.C. Inhibitory effects of isoquinoline-type alkaloids on leukemic cell growth and macromolecule biosynthesis. Gaoxiong Yi Xue Ke Xue Za Zhi 1990, 6:58-65.
17. Kondo Y., Imai Y., Hojo H., Endo T., Nozoe S. Suppression of tumour cell growth and mitogen response by aporphine alkaloids, dicentrine, glaucine, corydine, and apomorphine. J Pharmacobiodyn 1990, 13:426-431.
18. Huang R.L., Chen C.C., Huang Y.L., Ou J.C., Hu C.P., Chen C.F., et al. Anti-tumour effects of d-dicentrine from the root of Lindera megaphylla. Planta Med 1998, 64:212-215.
19. Woo S.H., Sun N.J., Cassady J.M., Snapka R.M. Topoisomerase II inhibition by aporphine alkaloids. Biochem Pharmacol 1999, 57:1141-1145.
20. Stévigny C., Bailly C., Quetin-Leclercq J. Cytotoxic and anti-tumour potentialities of aporphinoid alkaloids. Curr Med Chem Anticancer Agents 2005, 5:173-182.
21. Huang H.S., Nagane M., Klingbeil C.K., Lin H., Nishikawa R., Ji X.D., et al. The enhanced tumourigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signalling. J Biol Chem 1997, 272:2927-2935.
22. Nagane M., Coufal F., Lin H., Bögler O., Cavenee W.K., Huang H.J. A common mutant epidermal growth factor receptor confers enhanced tumourigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996, 56:5079-5086.
23. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity using human and other tumour cell lines. Cancer Res 1988, 48:4827-4833.
24. Konkimalla V.B., Blunder M., Korn B., Soomro S.A., Jansen H., Chang W., et al. Effect of artemisinins and other endoperoxides on nitric oxide-related signalling pathway in RAW 264.7 mouse macrophage cells. Nitric Oxide 2008, 19:184-191.
25. Eberwine J., Yeh H., Miyashiro K., Cao Y., Nair S., Finnell R., et al. Analysis of gene expression in single live neurons. Proc Natl Acad Sci USA 1992, 89:3010-3014.
26. Nagane M., Levitzki A., Gazit A., Cavenee W.K., Huang H.J. Drug resistance of human glioblastoma cells conferred by tumour-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3 like proteases. Proc Natl Acad Sci USA 1998, 95:5724-5729.
27. Efferth T., Sauerbrey A., Olbrich A., Gebhart E., Rauch P., Weber H.O., et al. Molecular modes of action of artesunate in tumour cell lines. Mol Pharmacol 2003, 64:382-394.
28. Efferth T., Gebhart E., Ross D.D., Sauerbrey A. Identification of gene expression profiles predicting tumour cell response to L-alanosine. Biochem Pharmacol 2003, 66:613-621.
29. Efferth T., Sauerbrey A., Halatsch M.E., Ross D.D., Gebhart E. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumour cell lines. Naunyn Schmiedebergs Arch Pharmacol 2003, 367:56-67.
30. Wosikowski K., Schuurhuis D., Kops G.J., Saceda M., Bates S.E. Altered gene expression in drug-resistant human breast cancer cells. Clin Cancer Res 1997, 3:2405-2414.
31. Zhou B.N., Johnson R.K., Mattern M.R., Wang X., Hecht S.M., Beck H.T., et al. Isolation and biochemical characterization of a new topoisomerase I inhibitor from Ocotea leucoxylon. J Nat Prod 2000, 63:217-221.
32. Marks J.L. EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. J Thoracic Oncol 2008, 3:805.
33. Markovits J., Larsen A.K., Ségal-Bendirdjian E., Fossé P., Saucier J.M., Gazit A., et al. Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives. Biochem Pharmacol 1994, 48:549-560.
34. Allen G.C., Lubas S., Wax M.K., Devore R.F. Epidermal growth factor regulates topoisomerase II activity and drug sensitivity in human KB cells. Otolaryngol Head Neck Surg 1996, 114:785-792.
35. Koizumi F., Kanzawa F., Ueda Y., Koh Y., Tsukiyama S., Taguchi F., et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (" Iressa" ) and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004, 108:464-472.
36. Treszezamsky A.D., Kachnic L.A., Feng Z., Zhang J., Tokadjian C., Powell S.N. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double strand breaks via topoisomerase II. Cancer Res 2007, 67:7078-7081.
37. Efferth T., Fabry U., Osieka R. Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 1997, 11:1180-1186.
38. Johansson M., Persson J.L. Cancer therapy: targeting cell cycle regulators. Anticancer Agents Med Chem 2008, 8:723-731.
39. Efferth T., Fabry U., Glatte P., Osieka R. Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells. J Cancer Res Clin Oncol 1995, 121:648-656.
40. Tadaki S., Nozaka T., Yamada S., Ishino M., Morimoto I., Tanaka A., et al. Clastogenicity of aporphine alkaloids in vitro. J Pharmacobiodyn 1992, 15:501-512.
41. Wong P.S., Li W., Vogel C.F., Matsumura F. Characterization of MCF mammary epithelial cells over-expressing the Arylhydrocarbon receptor (AhR). BMC Cancer 2009, 9:234.
42. Zudaire E., Cuesta N., Murty V., Woodson K., Adams L., Gonzalez N., et al. The aryl hydrocarbon receptor repressor is a putative tumour suppressor gene in multiple human cancers. J Clin Invest 2008, 118:640-650.
43. Mathieu M.C., Lapierre I., Brault K., Raymond M. Aromatic hydrocarbon receptor (AhR). AhR nuclear translocator- and p53-mediated induction of the murine multidrug resistance mdr1 gene by 3-methylcholanthrene and benzo(a)pyrene in hepatoma cells. J Biol Chem 2001, 276:4819-4827.
44. Teng C.M., Yu S.M., Ko F.N., Chen C.C., Huang Y.L., Huang T.F., et al. A natural vascular alpha 1-adrenoceptor antagonist, isolated from Lindera megaphylla. Br J Pharmacol 1991, 104:651-656.
45. Yu S.M., Hsu S.Y., Ko F.N., Chen C.C., Huang Y.L., Huang T.F., et al. Haemodynamic effects of dicentrine, a novel alpha 1-adrenoceptor antagonist: comparison with prazosin in spontaneously hypertensive and normotensive Wistar-Kyoto rats. Br J Pharmacol 1992, 106:797-801.
46. Yu S.M., Ko F.N., Chueh S.C., Chen J., Chen S.C., Chen C.C., et al. Effects of dicentrine, a novel alpha 1-adrenoceptor antagonist, on human hyperplastic prostates. Eur J Pharmacol 1994, 252:29-34.
47. Mustafa M.R., Achike F.I. Dicentrine is preferentially antagonistic to rat aortic than splenic alpha 1-adrenoreceptor stimulation. Acta Pharmacol Sin 2000, 21:1165-1168.
48. Yu S.M., Kang Y.F., Chen C.C., Teng C.M. Effects of dicentrine on haemodynamic, plasma lipid, lipoprotein level and vascular reactivity in hyperlipidaemic rats. Br J Pharmacol 1993, 108:1055-1061.
49. Young M.L., Su M.J., Wu M.H., Chen C.C. The electrophysiological effects of dicentrine on the conduction system of rabbit heart. Br J Pharmacol 1994, 113:69-76.
50. Chang K.C., Lo H.M., Lin F.Y., Tseng Y.Z., Ko F.N., Teng C.M. Effects of dicentrine on the mechanical properties of systemic arterial trees in dogs. J Cardiovasc Pharmacol 1995, 26:169-176.
51. Su M.J., Nieh Y.C., Huang H.W., Chen C.C. Dicentrine, an alpha-adrenoceptor antagonist with sodium and potassium channel blocking activities. Naunyn Schmiedebergs Arch Pharmacol 1994, 349:42-49.
52. Yu S.M., Chen C.C., Ko F.N., Huang Y.L., Huang T.F., Teng C.M. Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cyclic AMP level of rabbit platelets. Biochem Pharmacol 1992, 43:323-329.